Royalty Report: Drugs, Pharmaceuticals, Disease – Collection: 6473

$150.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 6

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 6

Primary Industries

  • Drugs
  • Pharmaceuticals
  • Disease
  • Therapeutic
  • Respiratory

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 6473

License Grant
The Company entered into its collaboration agreement to develop and commercialize a long-acting beta2 agonist (LABA) product candidate both as a single agent new medicine for the treatment of chronic obstructive pulmonary disease (COPD) and as part of a new combination medicine with an inhaled corticosteroid (ICS) for the treatment of asthma and/or a long-acting muscarinic antagonist (LAMA) for COPD.
License Property
The collaboration's resources are focused on the development of the lead LABA, GW642444, together with fluticasone furoate.
Field of Use
The rights granted apply to the healthcare industry.

IPSCIO Record ID: 27658

License Grant
The Licensor has rights to certain respiratory programs partnered with the Licensee, including FF/UMEC/VI (the closed triple) for the treatment of COPD.
License Property
Closed Triple or FF/UMEC/VI (fluticasone furoate/umeclidinium bromide/vilanterol)   The closed triple program seeks to provide the activity of an inhaled corticosteroid (FF) plus two bronchodilators (UMEC, a LAMA, and VI, a long-acting beta2agonist or LABA) in a single delivery device.

The aim of this study was to evaluate the systemic pharmacokinetics, systemic pharmacodynamics and safety and tolerability of UMEC/VI when administered as a blended combination in one strip and co-administered with FF in the second strip in the same novel dry powder inhaler (NDPI), as a new triple fixed dose combination product (FF/UMEC/VI).

Field of Use
The Licensee is a limited liability company formed to hold rights to certain earlier-stage respiratory programs partnered with the Licensee, including FF/UMEC/VI (the closed triple) for COPD.

IPSCIO Record ID: 213206

License Grant
The Irish Licensor grants the Licensee a worldwide license for the use of Trelegy Ellipta for the treatment of chronic obstructive pulmonary disease.
License Property
Trelegy Ellipta is a prescription medication used to treat chronic obstructive pulmonary disease (COPD), a group of diseases that includes chronic bronchitis and emphysema.

COPD is a type of obstructive lung disease characterized by long-term breathing problems and poor airflow.

Field of Use
This agreement pertains to the drug industry.

IPSCIO Record ID: 7592

License Grant
Licensor grants to Licensee the exclusive license to make, have made, use and develop collaboration products, commercialize, sell, offer for sale and import collaboration products and manufacture, to make and have made API compound or formulated collaboration product in the territory.
License Property
The collaboration product means any of the long-acting ß2 adrenoceptor agonists.
Long-acting ß2 adrenoceptor agonist or LABA means a chemical entity that selectively binds to human ß2 adrenoceptors and activates certain human ß2 adrenoceptors.

API compound means bulk quantities of active pharmaceutical ingredient compound prior to the commencement of secondary manufacturing resulting in a collaboration product.

Field of Use
The field of use is the human pharmaceutical use of long-acting ß2 adrenoceptor agonists for the treatment and/or prophylaxis of respiratory diseases.

IPSCIO Record ID: 7392

License Grant
Licensee Licensed the Company’s bifunctional muscarinic antagonist-beta2 agonist (MABA) program for the treatment of COPD, and  the Company and Licensee expanded the MABA program by adding six additional Theravance-discovered preclinical MABA compounds.
License Property
Both Licensee and the Company have agreed not to conduct any MABA clinical studies outside of the strategic alliance so long as Licensee is in possession of the Additional MABAs.
Field of Use
Licensee is obligated to use diligent efforts to develop and commercialize at least one MABA within the MABA program, but may terminate progression of any or all Additional MABAs at any time and return them to the Company, at which point the Company may develop and commercialize such Additional MABAs alone or with a third party.

IPSCIO Record ID: 6157

License Grant
The Licensee entered into a licensing agreement with a former shareholder for the commercialization of either of the VPAC2 analogs for any purpose.
License Property
Diabetes – VPAC2 agonists exert their effects through a separate receptor pathway than incretinin mimetic drugs like GLP-1 agonists ((i)Byetta®), and DPP-IV inhibitors ((ii)Januvia®). By targeting selective VPAC2 receptors, the FM-TP2000 series of analogs are designed to mimic the natural, neuronal signal, rather than the hormonal one, to stimulate beta cells to release insulin in a glucose-dependent fashion. This provides an alternative therapeutic approach, which could achieve benefits similar to Byetta, but may also be complementary in effect.

Inflammatory Lung Disease  – VPAC2 agonists have bronchodilating, and anti-inflammatory effects. By targeting VPAC2 receptors, the FM-TP3000 series of compounds are designed to suppress the release of inflammatory mediators (TNF-alpha, IL-12), as well as suppressing the eosinophil response to stimuli. This provides an alternate therapeutic approach to treating asthma, chronic obstructive pulmonary disease (COPD), and Pulmonary Arterial Hypertension (PAH).

Field of Use
The rights granted apply to the medical industry.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.